Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
543.57B
Market cap543.57B
Price-Earnings ratio
26.69
Price-Earnings ratio26.69
Dividend yield
2.25%
Dividend yield2.25%
Average volume
7.67M
Average volume7.67M
High today
$232.00
High today$232.00
Low today
$225.71
Low today$225.71
Open price
$230.88
Open price$230.88
Volume
3.10M
Volume3.10M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$149.04
52 Week low$149.04

Stock Snapshot

The current Johnson & Johnson(JNJ) stock price is $225.81, with a market capitalization of 543.57B. The stock trades at a price-to-earnings (P/E) ratio of 26.69 and offers a dividend yield of 2.3%.

During the trading session on 2026-05-29, Johnson & Johnson(JNJ) shares reached a daily high of $232.00 and a low of $225.71. At a current price of $225.81, the stock is +0.0% higher than the low and still -2.7% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 3.1M, versus its average volume of 7.67M.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $149.04.

Over the past 52 weeks, Johnson & Johnson(JNJ) stock has traded between a high of $251.71 and a low of $149.04.

JNJ News

TipRanks 5h
Johnson & Johnson reports new data from Phase 3 MajesTEC-9 study

Johnson & Johnson announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progres...

CNBC 5h
J&J CEO Joaquin Duato: It's our mission to become the number 1 company in oncology by 2030 - CNBC

...

J&J CEO Joaquin Duato: It's our mission to become the number 1 company in oncology by 2030 - CNBC
Simply Wall St 17h
Johnson And Johnson MedTech Moves And What They Could Mean For Investors

Johnson & Johnson subsidiaries are integrating Gemtrack radiofrequency tracking technology from MinMaxMedical into DePuy Synthes orthopedic products. The compa...

Johnson And Johnson MedTech Moves And What They Could Mean For Investors

Analyst ratings

63%

of 27 ratings
Buy
63%
Hold
29.6%
Sell
7.4%

More JNJ News

TipRanks 18h
J&J says FDA approves Tremfya label expansion

Johnson & Johnson announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application to include evidence in the TREM...

Nasdaq 1d
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?

Johnson & Johnson’s JNJ stock has risen 11.8% so far this year. One of the biggest drivers of the increase was J&J’s robust first-quarter 2026 results, as it be...

J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
The Wall Street Journal 1d
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Using tie-ups has long rewarded J&J, but it sometimes creates awkward situations. Chen Haoming / Zuma Press Johnson & Johnson JNJ 0.48 %increase; green up poin...

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Nasdaq 3d
President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?

Key Points Trump is looking to lower prescription drug prices in ways that could harm the profits of drugmakers in the U.S. Even if that happens, diversified...

President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks?
24/7 Wall St. 3d
Inflation Adjusted Dividend Income: How to Replace $80,000 in Today's Dollars 20 Years From Now

Inflation Adjusted Dividend Income: How to Replace $80,000 in Today’s Dollars 20 Years From Now By Drew Wood Published May 26, 9:32AM EDT Quick Read Johnson &...

Inflation Adjusted Dividend Income: How to Replace $80,000 in Today's Dollars 20 Years From Now
Simply Wall St 4d
A Look At Johnson & Johnson Valuation As Investor Interest Builds Around Recent Performance Metrics

Advertisement Event overview and why Johnson & Johnson is on investors’ radar Johnson & Johnson (JNJ) stock is drawing attention after fresh performance metri...

A Look At Johnson & Johnson Valuation As Investor Interest Builds Around Recent Performance Metrics
Nasdaq 4d
Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market

Key Points Johnson & Johnson is a leader in the pharmaceutical and medical device markets. Consumers don't usually have many choices when it comes to their me...

Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.